Welcome to our dedicated page for Anavex Life Sciences news (Ticker: AVXL), a resource for investors and traders seeking the latest updates and insights on Anavex Life Sciences stock.
Anavex Life Sciences Corp. reports developments as a clinical-stage biopharmaceutical company focused on central nervous system disorders, including Alzheimer’s disease, Parkinson’s disease, schizophrenia, Rett syndrome, and other neurodevelopmental, neurodegenerative, and rare diseases. Company news frequently centers on blarcamesine, its orally administered lead candidate, along with precision-medicine analyses using genomic and biomarker data.
Recurring updates include clinical and preclinical data presentations, scientific findings related to autophagy, synaptic dysfunction, SIGMAR1 biology, and disease mechanisms, as well as regulatory communications with the FDA and EMA. News also covers financial results, healthcare conference participation, board composition, executive leadership changes, and other corporate governance matters.
Anavex (Nasdaq: AVXL) said the CHMP delivered a negative trend vote on its MAA for oral blarcamesine for early Alzheimer’s disease after an oral explanation; a formal CHMP opinion is expected at the December meeting.
The company intends to request re-examination of the CHMP opinion when adopted and will provide additional biomarker data. Separately, FDA CDER advised Anavex to request a meeting to discuss its Alzheimer’s clinical trial results.
Anavex Life Sciences (Nasdaq: AVXL) reported long-term clinical benefit for oral blarcamesine in early Alzheimer’s disease versus externally matched ADNI controls over 144 weeks.
Key outcomes: ADAS-Cog13 mean change differences were −2.68 points at 48 weeks, −6.41 points at 96 weeks, and −12.78 points at 144 weeks (all p < 0.0001). The company reports an estimated 77.4 weeks (≈17.8 months) of “time saved” versus ADNI. Blarcamesine showed a favorable safety profile with no treatment-related deaths reported.
The release also reiterates a proposed mechanism—SIGMAR1 activation restoring impaired autophagy upstream of amyloid and tau—and notes the data will be published and presented at international Alzheimer’s conferences. The drug remains investigational with no guarantee of regulatory approval.
Anavex (Nasdaq: AVXL) announced an oral presentation delivered by Prof. Dr. Timo Grimmer, MD, member of the company's Scientific Advisory Board and National Coordinating Investigator for the blarcamesine Phase IIb/III ANAVEX®2-73-AD-004 study, at the 35th Alzheimer Europe Conference on October 10, 2025.
The presentation, titled “Advancing Alzheimer’s Disease Care: Convenience for Both Patients and Families with Oral Blarcamesine,” is available on Anavex’s investors website.
This release discusses investigational uses of an agent in development and does not draw conclusions about efficacy or safety; there is no guarantee the investigational product will complete clinical development or obtain health authority approval.
Anavex Life Sciences (NASDAQ:AVXL) has successfully developed a new once-daily oral tablet formulation for its ANAVEX®3-71 program. The Phase 1b clinical trial (ANAVEX3-71-002) demonstrated that the modified-release tablet shows superior pharmacokinetics compared to the current immediate-release capsule.
The study confirmed the safety and tolerability of the new formulation in both male and female adults aged 18 and older. ANAVEX®3-71, a dual SIGMAR1 receptor agonist and M1 positive allosteric modulator, aims to treat schizophrenia and neurodegenerative disorders with potential benefits across all symptom domains without standard antipsychotic side effects.
Anavex Life Sciences (NASDAQ:AVXL) announced positive topline results from its Phase 2 clinical study of ANAVEX®3-71 for treating schizophrenia in adults on stable antipsychotic medication. The study successfully met its primary endpoint, demonstrating safety and tolerability with no serious or severe treatment-emergent adverse events.
The trial showed encouraging trends in secondary and exploratory analyses, including positive changes in EEG and ERP biomarkers. Notably, the study revealed reduced levels of GFAP, a neuroinflammation marker, in treated participants compared to placebo, suggesting potential disease-modifying effects. ANAVEX®3-71, a dual SIGMAR1 receptor agonist and M1 positive allosteric modulator, aims to treat all symptom domains of schizophrenia without standard antipsychotic side effects.
Anavex Life Sciences (NASDAQ:AVXL) has published results from its Phase IIb/III trial of oral blarcamesine for early Alzheimer's disease treatment. The study demonstrates that the once-daily oral medication showed significant clinical efficacy and improved Quality of Life (QoL-AD) scores in patients.
Using a Precision Medicine approach, the treatment benefited up to 70% of Alzheimer's disease participants with unprecedented effect size. The drug demonstrated superior clinical efficacy versus approved therapies, with a strong safety profile and no requirement for routine MRI monitoring.
The results are currently available on medRxiv as a preprint and are being submitted to a peer-reviewed medical journal. The company will continue evaluating the Phase IIb/III early Alzheimer's disease and ATTENTION-AD trial data for future presentations at international conferences.
Anavex Life Sciences (NASDAQ:AVXL) has announced groundbreaking results from its Phase IIb/III Alzheimer's disease trial for oral blarcamesine. The drug demonstrated remarkable cognitive stabilization in early Alzheimer's patients, with outcomes approaching normal aging profiles. Key findings include an 84.7% reduction in cognitive decline compared to placebo on the ADAS-Cog13 endpoint at 48 weeks.
The study's Precision Medicine population showed minimal decline, with a 48-week change from baseline of 0.853 on ADAS-Cog13 and 0.465 on CDR-SB, comparable to prodromal aging adults. The treatment could benefit up to 70% of early Alzheimer's patients through its novel mechanism of autophagy restoration via SIGMAR1 activation, representing a significant advancement in individualized Alzheimer's care.
Anavex Life Sciences (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing treatments for neurological disorders, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference.
CEO Christopher U. Missling, PhD, will deliver a presentation on September 9, 2025, at 1:00 p.m. ET at the Lotte New York Palace. The company will provide updates on its innovative treatments for conditions including Alzheimer's disease, Parkinson's disease, and Rett syndrome. Investors can access the presentation through a live audio webcast on the company's website.
Anavex Life Sciences (NASDAQ:AVXL) announced a new peer-reviewed publication in iScience journal that details the precise autophagy mechanism of their drug blarcamesine. The study confirms how blarcamesine restores impaired autophagy through S1R/SIGMAR1 activation, acting upstream of amyloid and tau pathologies at the molecular level.
The research validates the specific S1R-localized motif's role in promoting autophagosome biogenesis, autophagic cargo reception, and lysosome fusion. This mechanism is particularly significant for treating neurodegenerative conditions, as S1R/SIGMAR1 activation helps reduce toxic Aβ, tau, and neuroinflammation while promoting neurogenesis and regulating cellular functions.
Anavex Life Sciences (NASDAQ:AVXL) announced a new peer-reviewed publication in Neuroscience Letters demonstrating that blarcamesine prevented cognitive decline in an Alzheimer's disease animal model. The study showed that pre-treatment with blarcamesine successfully prevented Amyloid beta-induced memory impairment and brain oxidative injury.
The research confirmed that blarcamesine works through SIGMAR1 activation, which enhances autophagy and helps normalize Aβ production. The drug, administered as a once-daily oral pill, demonstrated significant protection in pre-treated animals, showing less vulnerability to Aβ25-35-induced oxidative stress and reduced learning and memory deficits compared to placebo-controlled mice.